Edwards Lifesciences Corporation $EW Shares Bought by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund lifted its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 28.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 39,851 shares of the medical research company’s stock after buying an additional 8,884 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Edwards Lifesciences were worth $3,191,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Geneos Wealth Management Inc. grew its stake in Edwards Lifesciences by 3.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 8,545 shares of the medical research company’s stock worth $684,000 after acquiring an additional 254 shares during the period. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Edwards Lifesciences by 29.3% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 16,646 shares of the medical research company’s stock worth $1,333,000 after purchasing an additional 3,768 shares during the period. Sigma Planning Corp boosted its holdings in shares of Edwards Lifesciences by 8.2% during the first quarter. Sigma Planning Corp now owns 3,806 shares of the medical research company’s stock worth $305,000 after purchasing an additional 288 shares during the last quarter. Checchi Capital Advisers LLC boosted its holdings in shares of Edwards Lifesciences by 22.1% during the first quarter. Checchi Capital Advisers LLC now owns 4,511 shares of the medical research company’s stock worth $361,000 after purchasing an additional 815 shares during the last quarter. Finally, Nwam LLC grew its position in shares of Edwards Lifesciences by 2.8% in the first quarter. Nwam LLC now owns 32,909 shares of the medical research company’s stock valued at $2,635,000 after purchasing an additional 904 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE EW opened at $85.72 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The firm has a market capitalization of $49.36 billion, a P/E ratio of 45.60, a P/E/G ratio of 2.15 and a beta of 0.86. The business’s 50-day simple moving average is $87.34 and its 200-day simple moving average is $83.92.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. During the same quarter in the prior year, the company earned $0.64 EPS. The company’s revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Activity

In related news, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the transaction, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 45,577 shares of company stock valued at $3,855,527. Company insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

EW has been the subject of several analyst reports. Barclays reiterated an “overweight” rating and issued a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Citigroup lifted their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Truist Financial increased their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a report on Thursday. Finally, Wall Street Zen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $98.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.